Zhitong Financial App News, Peijia Medical-B (09996) issued an announcement that the company's revenue for the six months ended June 30, 2023 increased by about 85.2% RMB93.6% to about RMB 220 million-230 million.
The increase in revenue is mainly due to the following reasons: group transcatheter aortic valve replacement products (including the first generation product TaurusOne), the announcement said.And the second generation recyclable product TaurusElite) accelerate commercialization and further expand market share; the Group's existing neural intervention products (including TethysIntermediate guide catheter, SacSpeedBalloon dilation catheter, JasperIntracranial Electrolytic detachable coils and SyphonetThrombectomy stents, etc.) continue to contribute to the group's revenue growth; and the ischemic products (including Fastunnel) approved by the State Drug Administration for registration in the second quarter of 2022Transport balloon dilatation catheter, etc.) began to be commercialized, contributing to the group's revenue growth.